PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials - Scorecard - MDSpire
Advertisement
PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials
Clinical Scorecard: Combination of PD-1/PD-L1 Inhibitors and Chemotherapy as Initial Treatment for Advanced or Metastatic Endometrial Cancer: A Systematic Review and Meta-Analysis of Randomized Trials
At a Glance
Category
Detail
Condition
Key Mechanisms
Remove unsupported claim about enhanced immune response and survival outcomes.
Target Population
Care Setting
Key Highlights
0
Guideline-Based Recommendations
Diagnosis
Management
A
t
t
r
i
b
u
t
e
r
e
c
o
m
m
e
n
d
a
t
i
o
n
s
t
o
s
p
e
c
i
f
i
c
g
u
i
d
e
l
i
n
e
s
o
r
e
x
p
e
r
t
s
o
u
r
c
e
s
.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with advanced or metastatic endometrial cancer, including both dMMR and pMMR subtypes.
Combination therapy shows improved survival outcomes compared to chemotherapy alone.
